More specifically, co-administration of monalizumab and cetuximab, an anti-EGFR antibody, in patients with head and neck squamous cell carcinoma (HNSCC) resulted in the induction of anti-tumor memory [27,39]. Here, EGFR is linked to head and neck squamous cell carcinoma.